global drug cap 
global inequities access pharmaceutical products exist rich poor countries market government failures well huge income differences multiple policies required address global drug gap three categories pharmaceutical products: essential drugs new drugs yet-to-be-developed drugs policies combine "push" approaches financial subsidies support targeted drug development "pull" approaches financial incentives market guarantees "process" approaches aimed improved institutional-capacity constructive solutions needed can protect incentives research development reduce inequities access 
